Narrow search
Showing 1 - 10 of 915
Cover Image
Reference pricing, competition, and pharmaceutical expenditures : theory and evidence from a natural experiment
Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2010
-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …
Persistent link: https://www.econbiz.de/10008749029
Cover Image
Reference pricing, competition, and pharmaceutical expenditures : theory and evidence from a natural experiment
Brekke, Kurt R.; Holmas, Tor Helge; Straume, Odd Rune - In: Journal of public economics 95 (2011) 7/8, pp. 624-638
Persistent link: https://www.econbiz.de/10009270541
Cover Image
Reference Pricing, Competition, and Pharmaceutical Expenditures : Theory and Evidence from a Natural Experiment
Brekke, Kurt Richard; Holmas, Tor Helge; Straume, Odd Rune - 2021
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...
Persistent link: https://www.econbiz.de/10013316129
Cover Image
Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals
Herr, Annika; Suppliet, Moritz - In: Journal of health economics 56 (2017), pp. 19-29
Persistent link: https://www.econbiz.de/10011798902
Cover Image
Price controls for medical innovations in a life cycle perspective
Sorek, Gilad - In: Health economics 23 (2014) 1, pp. 108-116
Persistent link: https://www.econbiz.de/10010257208
Cover Image
Pricing the pharmaceuticals when the ability to pay differs
Kanniainen, Vesa; Laine, Juha; Linnosmaa, Ismo - In: Journal of the Finnish Economic Association : JFEA 2 (2021) 1, pp. 25-48
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...
Persistent link: https://www.econbiz.de/10013286496
Cover Image
Pricing the pharmaceuticals when the ability to pay differs : taking vertical equity seriously
Kanniainen, Vesa; Laine, Juha; Linnosmaa, Ismo - 2019
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012157261
Cover Image
The effects of drug market regulation on pharmaceutical prices in Europe : overview and evidence from the market of ACE inhibitors
Schulenburg, Fritz von der; Vandoros, Sotiris; Kanavos, … - In: Health economics review 1 (2011) 18, pp. 1-8
in reducing pharmaceuticals prices. Results are not as strong for demand side measures. Profit controls and the use of …
Persistent link: https://www.econbiz.de/10009503923
Cover Image
Reference pricing and cost-sharing : theory and evidence on German off-patent drugs ; conference paper
Herr, Annika; Stühmeier, Torben; Wenzel, Tobias - 2014
-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference …
Persistent link: https://www.econbiz.de/10010489291
Cover Image
More cost-sharing, less cost? : evidence on reference price drugs
Herr, Annika; Stühmeier, Torben; Wenzel, Tobias - In: Health economics 32 (2023) 2, pp. 413-435
Persistent link: https://www.econbiz.de/10014266816